These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30207179)

  • 1. Pazopanib in relapsed osteosarcoma patients: report on 15 cases.
    Longhi A; Paioli A; Palmerini E; Cesari M; Abate ME; Setola E; Spinnato P; Donati D; Hompland I; Boye K
    Acta Oncol; 2019 Jan; 58(1):124-128. PubMed ID: 30207179
    [No Abstract]   [Full Text] [Related]  

  • 2. Response of refractory Ewing sarcoma to pazopanib.
    Alcindor T
    Acta Oncol; 2015 Jul; 54(7):1063-4. PubMed ID: 25345493
    [No Abstract]   [Full Text] [Related]  

  • 3. Pazopanib for second recurrence of osteosarcoma in pediatric patients.
    Umeda K; Kato I; Saida S; Okamoto T; Adachi S
    Pediatr Int; 2017 Aug; 59(8):937-938. PubMed ID: 28685501
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to Pazopanib in Patients With Relapsed Osteosarcoma.
    Elete KR; Albritton KH; Akers LJ; Basha R; Ray A
    J Pediatr Hematol Oncol; 2020 May; 42(4):e254-e257. PubMed ID: 30531600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study.
    Huang YJ; He AN; Sun YJ; Shen Z; Min DL; Yao Y
    Asian Pac J Cancer Prev; 2015; 16(6):2391-5. PubMed ID: 25824770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients.
    Safwat A; Boysen A; Lücke A; Rossen P
    Acta Oncol; 2014 Oct; 53(10):1451-4. PubMed ID: 25143189
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML).
    Kessler T; Koschmieder S; Schliemann C; Crysandt M; Mikesch JH; von Stillfried S; Stelljes M; Pohlen M; Lenz G; Kirsch A; Vehring K; Wardelmann E; Hartmann W; Bormann E; Gerss J; Brümmendorf TH; Müller-Tidow C; Berdel WE
    Ann Hematol; 2019 Jun; 98(6):1393-1401. PubMed ID: 30903275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib therapy for desmoid tumors in adolescent and young adult patients.
    Agresta L; Kim H; Turpin BK; Nagarajan R; Plemmons A; Szabo S; Dasgupta R; Sorger JI; Pressey JG
    Pediatr Blood Cancer; 2018 Jun; 65(6):e26968. PubMed ID: 29384266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group.
    Isakoff MS; Goldsby R; Villaluna D; Krailo MD; Hingorani P; Collier A; Morris CD; Kolb EA; Doski JJ; Womer RB; Gorlick R; Janeway KA
    Pediatr Blood Cancer; 2019 Feb; 66(2):e27524. PubMed ID: 30378256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
    Koinis F; Agelaki S; Karavassilis V; Kentepozidis N; Samantas E; Peroukidis S; Katsaounis P; Hartabilas E; Varthalitis II; Messaritakis I; Fountzilas G; Georgoulias V; Kotsakis A
    Br J Cancer; 2017 Jun; 117(1):8-14. PubMed ID: 28510571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma.
    Iacovelli R; Verzoni E; Grassi P; Farcomeni A; de Braud F; Procopio G
    Tumori; 2014; 100(6):e282-5. PubMed ID: 25688511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uveal metastasis and myasthenia gravis in a patient with recurrent renal cell carcinoma treated with pazopanib.
    Jebb A; Hadden P; Broom RJ
    Clin Genitourin Cancer; 2014 Aug; 12(4):e143-6. PubMed ID: 24656526
    [No Abstract]   [Full Text] [Related]  

  • 13. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
    Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
    J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy.
    Yang J; Wang ZG; Cai HQ; Li YC; Xu YL
    Asian Pac J Cancer Prev; 2013; 14(8):4595-8. PubMed ID: 24083708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma.
    Pinciroli P; Won H; Iyer G; Canevari S; Colecchia M; Giannatempo P; Raggi D; Pierotti MA; De Braud FG; Solit DB; Rosenberg JE; Berger MF; Necchi A
    Clin Genitourin Cancer; 2016 Feb; 14(1):e81-90. PubMed ID: 26371421
    [No Abstract]   [Full Text] [Related]  

  • 16. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).
    Prince HM; Hönemann D; Spencer A; Rizzieri DA; Stadtmauer EA; Roberts AW; Bahlis N; Tricot G; Bell B; Demarini DJ; Benjamin Suttle A; Baker KL; Pandite LN
    Blood; 2009 May; 113(19):4819-20. PubMed ID: 19423744
    [No Abstract]   [Full Text] [Related]  

  • 17. Periosteal osteosarcoma--a European review of outcome.
    Grimer RJ; Bielack S; Flege S; Cannon SR; Foleras G; Andreeff I; Sokolov T; Taminiau A; Dominkus M; San-Julian M; Kollender Y; Gosheger G;
    Eur J Cancer; 2005 Dec; 41(18):2806-11. PubMed ID: 16290134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
    Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
    Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
    Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
    Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising management of pazopanib-induced liver toxicity.
    Vlenterie M; van Erp NP; van der Graaf WT
    Acta Oncol; 2015 Jul; 54(7):1064-6. PubMed ID: 25734660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.